These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 26789695)

  • 1. Safety of long acting muscarinic antagonists: are all these drugs always and equally safe?
    Melani AS; Sestini P
    Curr Med Res Opin; 2016 May; 32(5):975-7. PubMed ID: 26789695
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness analysis of umeclidinium/vilanterol for the management of patients with moderate to very severe COPD using an economic model.
    Wilson MR; Patel JG; Coleman A; McDade CL; Stanford RH; Earnshaw SR
    Int J Chron Obstruct Pulmon Dis; 2017; 12():997-1008. PubMed ID: 28392684
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative Cardiovascular and Cerebrovascular Safety of Inhaled Long-Acting Bronchodilators in Patients with Chronic Obstructive Pulmonary Disease: A Population-Based Cohort Study.
    Dong YH; Chang CH; Gagne JJ; Hsu CL; Lai MS
    Pharmacotherapy; 2016 Jan; 36(1):26-37. PubMed ID: 26799347
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The discovery and development of aclidinium bromide for the treatment of chronic obstructive pulmonary disease.
    Malerba M; Radaeli A; Santini G; Morjaria J; Mores N; Mondino C; Macis G; Montuschi P
    Expert Opin Drug Discov; 2018 Jun; 13(6):563-577. PubMed ID: 29616842
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Potential for long-acting muscarinic antagonists in chronic obstructive pulmonary disease.
    Joos GF
    Expert Opin Investig Drugs; 2010 Feb; 19(2):257-64. PubMed ID: 20047505
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized controlled trials and real-world observational studies in evaluating cardiovascular safety of inhaled bronchodilator therapy in COPD.
    Kardos P; Worsley S; Singh D; Román-Rodríguez M; Newby DE; Müllerová H
    Int J Chron Obstruct Pulmon Dis; 2016; 11():2885-2895. PubMed ID: 27932872
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative efficacy of long-acting muscarinic antagonist monotherapies in COPD: a systematic review and network meta-analysis.
    Ismaila AS; Huisman EL; Punekar YS; Karabis A
    Int J Chron Obstruct Pulmon Dis; 2015; 10():2495-517. PubMed ID: 26604738
    [TBL] [Abstract][Full Text] [Related]  

  • 8. LAMA/LABA vs ICS/LABA in the treatment of COPD in Japan based on the disease phenotypes.
    Hizawa N
    Int J Chron Obstruct Pulmon Dis; 2015; 10():1093-102. PubMed ID: 26089659
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety of inhaled long-acting anti-muscarinic agents in COPD.
    Hanania NA; Lareau SC; Yawn BP
    Postgrad Med; 2017 Jun; 129(5):500-512. PubMed ID: 28395575
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-acting muscarinic antagonists.
    Melani AS
    Expert Rev Clin Pharmacol; 2015; 8(4):479-501. PubMed ID: 26109098
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Umeclidinium for treating COPD: an evaluation of pharmacologic properties, safety and clinical use.
    Manickam R; Asija A; Aronow WS
    Expert Opin Drug Saf; 2014 Nov; 13(11):1555-61. PubMed ID: 25294427
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Umeclidinium for the treatment of chronic obstructive pulmonary disease.
    Segreti A; Calzetta L; Rogliani P; Cazzola M
    Expert Rev Respir Med; 2014 Dec; 8(6):665-71. PubMed ID: 25312239
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Practical considerations when prescribing a long-acting muscarinic antagonist for patients with COPD.
    D'Urzo AD; Kardos P; Wiseman R
    Int J Chron Obstruct Pulmon Dis; 2018; 13():1089-1104. PubMed ID: 29670345
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The combination of umeclidinium bromide and vilanterol in the management of chronic obstructive pulmonary disease: current evidence and future prospects.
    Feldman GJ; Edin A
    Ther Adv Respir Dis; 2013 Dec; 7(6):311-9. PubMed ID: 24004659
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of dual bronchodilators in COPD: A review of the current evidence for indacaterol/glycopyrronium.
    Ficker JH; Rabe KF; Welte T
    Pulm Pharmacol Ther; 2017 Aug; 45():19-33. PubMed ID: 28389258
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhaled Umeclidinium in COPD Patients: A Review and Meta-Analysis.
    Pleasants RA; Wang T; Gao J; Tang H; Donohue JF
    Drugs; 2016 Mar; 76(3):343-61. PubMed ID: 26755180
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk of adverse cardiovascular events with use of inhaled long-acting bronchodilators in management of chronic obstructive pulmonary disease.
    Wang MT; Lai JH; Tsai CL; Liou JT
    J Food Drug Anal; 2019 Jul; 27(3):657-670. PubMed ID: 31324282
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term (52 weeks) safety and tolerability of umeclidinium in Japanese patients with chronic obstructive pulmonary disease.
    Yamagata E; Soutome T; Hashimoto K; Mihara K; Tohda Y
    Curr Med Res Opin; 2016 May; 32(5):967-73. PubMed ID: 26782971
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Umeclidinium/vilanterol combination inhaler efficacy and potential impact on current chronic obstructive pulmonary disease management guidelines.
    Davidson JF; Donohue JF; Ohar JA
    Expert Opin Drug Saf; 2015 Feb; 14(2):317-24. PubMed ID: 25598422
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of Long-Acting Muscarinic Antagonist/Long-Acting β
    Petite SE
    Ann Pharmacother; 2017 Aug; 51(8):696-705. PubMed ID: 28410560
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.